John Latona, MD
Ophthalmology · Indianapolis, INNPI 1497700983
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,229 of the $18,060 with a category attached, or 73.2%. 33 manufacturers reported payments, led by Carl Zeiss Meditec Digital Innovations LLC at 25.5% of the total. Reporting peaked in 2024 at $7,091 and has fallen 69.3% since, to $2,175 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $46.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Digital Innovations LLC$5K
- Alcon$4K
- AbbVie$2K
- Mallinckrodt Hospital Products Inc.$1K
- Bausch & Lomb Americas Inc.$970
- Aerie Pharmaceuticals, Inc.$908
- plus $4K from 27 others
What the payments were for
- Food & beverage$13,22973%
- Education$2001%
- Gifts$190%
- Other$4,61226%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $4,612 |
| Alcon | 76 | $4,074 |
| AbbVie(2 entities) | 98 | $1,936 |
| Mallinckrodt Hospital Products Inc. | 27 | $1,185 |
| Bausch & Lomb Americas Inc. | 21 | $970 |
| Aerie Pharmaceuticals, Inc. | 21 | $908 |
| Sun Pharmaceutical Industries Inc. | 23 | $706 |
| Oyster Point Pharma, Inc. | 15 | $591 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $516 |
| Novartis | 16 | $336 |
| Sight Sciences, Inc. | 7 | $276 |
| ANI Pharmaceuticals, Inc. | 8 | $256 |
| Kala Pharmaceuticals, Inc. | 9 | $228 |
| Harrow Eye, LLC | 4 | $212 |
| Amgen(2 entities) | 5 | $185 |
| Carl Zeiss Meditec USA, Inc. | 4 | $159 |
| Dompe US, Inc. | 5 | $125 |
| Tarsus Pharmaceuticals, Inc. | 2 | $110 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $108 |
| NEW World Medical,inc. | 6 | $101 |
| Eyevance Pharmaceuticals LLC | 6 | $99 |
| Ocular Therapeutix, Inc. | 4 | $82 |
| Ivantis, Inc | 3 | $56 |
| Astellas Pharma US Inc | 2 | $46 |
| Thea Pharma Inc. | 2 | $41 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Glaukos Corporation | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alimera Sciences, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Carl Zeiss Meditec, Inc. | 1 | $14 |
| Rxsight Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,060 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 115 | $163,913 |
| LumiganBimatoprost | 139 | $79,074 |
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $37,746 |
| CombiganBrimonidine Tartrate/Timolol | 60 | $26,738 |
| XiidraLifitegrast | 16 | $24,928 |
| RhopressaNetarsudil Mesylate | 35 | $20,602 |
| Alphagan PBrimonidine Tartrate | 47 | $19,360 |
| Prednisolone Acetate | 394 | $18,855 |
| CequaCyclosporine | 11 | $15,535 |
| Ketorolac Tromethamine | 393 | $11,227 |
| Latanoprost | 1,031 | $10,664 |
| Brimonidine Tartrate | 465 | $9,644 |
| Dorzolamide Hcl | 308 | $7,408 |
| Travoprost | 31 | $6,284 |
| Brinzolamide | 29 | $5,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,936 | $289,085361 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $908 | $58,34985 claims |
| Bausch & Lomb Americas Inc.Xiidra | $970 | $24,92816 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $706 | $15,53511 claims |
| AlconSimbrinza | $4,074 | $4,87714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.